[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@LSciStartupNews LifeSci Startup

LifeSci Startup posts on X about $mirm, $kymr, ai, $100m the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXX +36%
• X Month XXXXX -XX%
• X Months XXXXXX +3,345%
• X Year XXXXXX +535%

Mentions: X #

• X Week X -XX%
• X Month XX -XX%
• X Months XX +911%
• X Year XX +267%

Followers: XXX #

• X Week XXX no change
• X Month XXX +1.90%
• X Months XXX +9.60%
• X Year XXX +14%

CreatorRank: undefined #

Social Influence

Social category influence finance XXXXX% vc firms XXXXX% stocks XXXXX%

Social topic influence $mirm #15, $kymr #30, ai 33.33%, $100m 16.67%, abingworth 16.67%, strong 16.67%, $dyn 16.67%, $42m 16.67%, $47m 16.67%, $820m XXXXX%

Top assets mentioned Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Kymera Therapeutics, Inc. Common Stock (KYMR) Dyne Therapeutics, Inc. Common Stock (DYN)

Top Social Posts

Top posts by engagements in the last XX hours

"Iambic Therapeutics has raised $100M+ to advance AI-designed medicines backed by investors including Abingworth Mubadala and Sequoia. The funding supports upcoming clinical programs and follows strong IAM1363 data and a new Jazz Pharma partnership"
X Link 2025-11-12T18:00Z XXX followers, XXX engagements

"Top LifeSci Startup news featured in our December 8th 2025 newsletter: $MIRM Acquiring Bluejay Therapeutics; Data From $DYN $KYMR; Tessel Bio Awarded $4.2M #healthcare #biotech #lifescience #HealthTech #AI"
X Link 2025-12-08T17:54Z XXX followers, XXX engagements

"PsiThera has spun out of Roivant with $47M in Series A funding and its QUAISAR platform that uses physics AI and supercomputing to accelerate early drug discovery before lab work begins. Roivant continues to back the company. More:"
X Link 2025-12-11T00:11Z XXX followers, XX engagements

"$MIRM is acquiring Bluejay Therapeutics in a deal worth up to $820M to add a late-stage asset for hepatitis D. The deal includes $250M cash $370M in stock and up to $200M in milestones. Lead asset brelovitug has Phase X data expected in 2H 2026"
X Link 2025-12-09T21:30Z XXX followers, XX engagements

"Kymera Therapeutics $KYMR closed an upsized public offering raising $692M in gross proceeds to advance its oral small-molecule degrader platform for immunological diseases"
X Link 2025-12-12T23:17Z XXX followers, XX engagements